Impact of pharmacist intervention in patients with Alzheimer's disease

Marcela Forgerini; Maria Teresa Herdeiro; Fernanda Mariana Oliveira; Rosa Camila Lucchetta; Marisa Veiga Capela; Patricia de Carvalho Mastroianni

doi:10.1590/s2175-97902022e19876

Authors

Marcela Forgerini Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil https://orcid.org/0000-0002-2905-8519
Maria Teresa Herdeiro Institute of Biomedicine - iBiMED, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal
Fernanda Mariana Oliveira Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil
Rosa Camila Lucchetta Federal University of Parana (UFPR), Brazil
Marisa Veiga Capela Department of Physics and Chemistry, São Paulo State University (UNESP), Araraquara, Brazil
Patricia de Carvalho Mastroianni Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil https://orcid.org/0000-0001-8467-7278

DOI:

https://doi.org/10.1590/s2175-97902022e19876%20

Keywords:

Elderly, Face-to-face, Medication adherence, Medication errors, Medication review

Abstract

To assess the therapy relative to indication, effectiveness, safety and adherence in patients with Alzheimer’s disease (AD). An interventional, prospective, non-randomized study was conducted in a single secondary care center in Brazil. The pharmacist-led medication therapy management (MTM) was conducted to detect drug-related problems (DRPs) at baseline and after six months of intervention. The health status outcomes (i.e. cognitive screening tests; levels of glucose; total cholesterol; triglycerides; thyroid stimulating hormone; serum free thyroxine and blood pressure) were measured. 66 patients with AD were included, of whom 55 patients completed the follow-up of six months. 36 patients (36/55) were non-adherent to AD drug therapy. Out of detected 166 DRPs, 116 were solved. Four patients were withdrawn from the AD protocol due to resolution of prodromal symptoms. On the conclusion of the study, the MTM improved and controlled blood pressure, glucose, total cholesterol, triglycerides levels (p<0.05). The pharmacist-led MTM was effective in solving 69.8% of DRPs, improving and controlling the clinical parameters evaluated.

Downloads

Download data is not yet available.

References

Alzheimer’s Association. Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2017;13,325-373. https://doi.org/10.1016/j.jalz.2017.02.001

» https://doi.org/10.1016/j.jalz.2017.02.001

Arismendi E, Martínez F, Antiñolo AT, Ibáñez MG. Evaluación e impacto de la intervención farmacéutica mediante seguimiento farmacoterapeutico a pacientes con enfermedad de alzheimer. Tese [Doutorado] - Universidad de Granada; 2012.

Benzi JRL, Mastroianni PC. Analysis of extemporaneous oral liquid from commercially available drugs in hospital. Braz J Pharm Sci. 2016;52,517-525. https://doi.org/10.1590/s1984-82502016000300017

» https://doi.org/10.1590/s1984-82502016000300017

Brasil. Ministério da Saude. Gabinete do Ministro. Portaria n. 529, de 1o de abril de 2013a. Institui o Programa Nacional de Segurança do Paciente (PNSP). D. Of. Bras. Seção 1. 2013; p.43-44.

Burns A, Iliffe S. Alzheimer’s disease. BMJ. 2009;338:b158. https://doi.org/10.1136/bmj.b158

» https://doi.org/10.1136/bmj.b158

Ceresini G, Lauretani F, Maggio M, Ceda GP, Morganti S, Usberti E, et al. Thyroid function abnormalities and cognitive impairment in elderly people: Results of the invecchiare in chianti study. J Am Geriatr Soc. 2009;57(1):89-93. https://doi.org/10.1111/j.1532-5415.2008.02080.x

» https://doi.org/10.1111/j.1532-5415.2008.02080.x

Cipolle RJ, Strand LM, Morley PC. Pharmaceutical Care Practice: The Patient Centered Approach to Medication Management. 3rd Edition, McGraw-Hill, Health Professions Division, New York. Pharmacol Pharm. 2012.

Costa AF, Chaves MLF, Picon PD, Krug BC, Gonçalves CBT, Amaral KM, et al. Protocolo Clínico e Diretrizes Terapêuticas - Doença de Alzheimer. Portaria conjunta No 13, 28 novembro 2017:147-167.

Crane PK, Walker R, Hubbard R, Li G, Nathan DM, Zheng H, et al. Glucose levels and risk of dementia. N Engl J Med. 2013;369(6):540-8. https://doi.org/10.1056/NEJMoa1215740

» https://doi.org/10.1056/NEJMoa1215740

Defrancesco M, Marksteiner J, Wolfgang FW Blasko. Use of benzodiazepines in Alzheimer’s disease: A systematic review of literature. Int J Neuropsychopharmacol. 2015;18(10):pyv055. https://doi.org/10.1093/ijnp/pyv055

» https://doi.org/10.1093/ijnp/pyv055

Des Jarlais DC, Lyles C, Crepaz N. Improving the Reporting Quality of Nonrandomized Evaluations of Behavioral and Public Health Interventions: The TREND Statement. Am J Public Health. 2004. https://doi.org/10.2105/AJPH.94.3.361

» https://doi.org/10.2105/AJPH.94.3.361

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198. https://doi.org/10.1016/0022-3956(75)90026-6

» https://doi.org/10.1016/0022-3956(75)90026-6

Forgerini M, Mastroianni PC. Monitoring compliance of Clinical Protocol and Therapeutic Guidelines for Alzheimer’s disease. Dement Neuropsychol. 2020;14(1):24-27. https://doi.org/10.1590/1980-57642020dn14-010004

» https://doi.org/10.1590/1980-57642020dn14-010004

Forgerini M, Herdeiro MT, Galduróz JCF, Mastroianni PC. Risk factors associated with drug therapy in the elderly with Alzheimer's disease. São Paulo Med J. 2020;138(3):216-218.

Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto E, Lanctot KL, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331:1169. https://doi.org/10.1136/bmj.38623.768588.47

» https://doi.org/10.1136/bmj.38623.768588.47

Gustafsson M, Sjölander M, Pfister B, Jonsson J, Schneede J, Lövheim H. Drug-related hospital admissions among old people with dementia. Eur J Clin Pharmacol. 2016;72(9):1143-53. https://doi.org/10.1007/s00228-016-2084-3

» https://doi.org/10.1007/s00228-016-2084-3

Hayes TL, Larimer N, Adami A, Kaye JA. Medication adherence in healthy elders: Small cognitive changes make a big difference. J Aging Health. 2009;21(4):567-80. https://doi.org/10.1177/0898264309332836

» https://doi.org/10.1177/0898264309332836

Høiseth G, Kristiansen KM, Kvande K, Tanum L, Lorentzen B, Refsum H. Benzodiazepines in geriatric psychiatry: What doctors report and what patients actually use. Drugs Aging. 2013;30:113-118. https://doi.org/10.1007/s40266-012-0045-9

» https://doi.org/10.1007/s40266-012-0045-9

Kelly J, D’Cruz G, Wright D. Patients with dysphagia: Experiences of taking medication. J Adv Nurs. 2010;66(1):82-91. https://doi.org/10.1111/j.1365-2648.2009.05145.x

» https://doi.org/10.1111/j.1365-2648.2009.05145.x

Lucchetta RC, da Mata BPM, Mastroianni PC. Association between Development of Dementia and Use of Benzodiazepines: A Systematic Review and Meta-analysis. Pharmacother. 2018;38(10):1010-1020. https://doi.org/10.1002/phar.2170

» https://doi.org/10.1002/phar.2170

Machuca-González M, Silva Castro MM. Evaluación de la farmacoterapia a partir de la enfermedad de base. Pharm Care Espana. 2010;12(1):192-194.

Manary MP, Boulding W, Staelin R, Glickman SW. The Patient Experience and Health Outcomes. N Engl J Med. 2013;368(3):201-3. https://doi.org/10.1056/NEJMp1211775

» https://doi.org/10.1056/NEJMp1211775

Mastroianni PC, Forgerini M. Compliance and Drug Related Problems in probable Alzheimer’s disease elderly. Int Psychogeriatr. 2019;31(11):1677-1678. https://doi.org/10.1017/S104161021800234X

» https://doi.org/10.1017/S104161021800234X

Mastroianni PC, Forgerini M. Drug administration adjustments for elderly patients with dysphagia: A case report. Dement Neuropsychol . 2018;12(1):97-100. https://doi.org/10.1590/1980-57642018dn12-010015

» https://doi.org/10.1590/1980-57642018dn12-010015

Matsuzaki T, Sasaki K, Hata J, Hirakawa Y, Fujimi K, Ninomiya T, et al. Association of Alzheimer disease pathology with abnormal lipid metabolism: The hisayama study. Neurology. 2011;77(11):1068-75. https://doi.org/10.1212/WNL.0b013e31822e145d

» https://doi.org/10.1212/WNL.0b013e31822e145d

Mehta DC, Short JL, Hilmer SN, Nicolazzo JA. Drug access to the central nervous system in Alzheimer’s disease: Preclinical and clinical insights. Pharm Res. 2015;32(3):819-39. https://doi.org/10.1007/s11095-014-1522-0

» https://doi.org/10.1007/s11095-014-1522-0

Mendonça SAM, Freitas EL, Oliveira DR. Competencies for the provision of comprehensive medication management services in an experiential learning project. PLoS One. 2017;12(9):e0185415. doi: 10.1371/journal.pone.0185415

» https://doi.org/10.1371/journal.pone.0185415

Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43(11):2412-2412. https://doi.org/10.1212/WNL.43.11.2412-a

» https://doi.org/10.1212/WNL.43.11.2412-a

Muliyala KP, Varghese M. The complex relationship between depression and dementia. Ann Indian Acad Neurol. 2010;13(6):69-73. https://doi.org/10.4103/0972-2327.74248

» https://doi.org/10.4103/0972-2327.74248

Nation DA, Delano-Wood L, Bangen KJ, Wierenga CE, Jak AJ, Hansen LA, et al. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed alzheimer’s disease. J Alzheimer’s Dis. 2012;30(3):595-603. https://doi.org/10.3233/JAD-2012-111697

» https://doi.org/10.3233/JAD-2012-111697

Nguyen TA, Gilmartin-Thomas J, Tan ECK, Kalisch-Ellett L, Eshetie T, Gillam M, et al. The impact of pharmacist interventions on quality use of medicines, quality of life, and health outcomes in people with dementia and/or cognitive impairment: A systematic review. J Alzheimer’s Dis. 2019;71(1):83-96. https://doi.org/10.3233/JAD-190162

» https://doi.org/10.3233/JAD-190162

Obreli-Neto PR, Guidoni CM, Oliveira Baldoni A, Pilger D, Cruciol-Souza JM, Gaeti-Franco, et al. Effect of a 36-month pharmaceutical care program on pharmacotherapy adherence in elderly diabetic and hypertensive patients. Int J Clin Pharm. 2011;33(4):642-9. https://doi.org/10.1007/s11096-011-9518-x

» https://doi.org/10.1007/s11096-011-9518-x

Organización Farmacéuticos Ibero-Latinoamericanos. Guía para la implantación de Servicios de Gestión Integral de la farmacoterapia. 2012. Acessed in 17 January, 2020.

Paradiso LM, Roughead EE, Gilbert AL, Cosh D, Nation RL, Barnes L, et al. Crushing or altering medications: what’s happening in residential aged-care facilities? Australas J Ageing. 2008;21(3):123-127. https://doi.org/10.1111/j.1741-6612.2002.tb00432.x

» https://doi.org/10.1111/j.1741-6612.2002.tb00432.x

Picon PD, Camozzato AL, Lapporte EA, Picon RV, Filho HM, Cerveira MO, et al. Increasing rational use of cholinesterase inhibitors for Alzheimer’s disease in Brazil: Public health strategy combining guideline with peer-review of prescriptions. Int J Technol Assess Health Care. 2010;26(2):205-10. https://doi.org/10.1017/S0266462310000097

» https://doi.org/10.1017/S0266462310000097

Potter GG, Steffens DC. Contribution of depression to cognitive impairment and dementia in older adults. Neurologist. 2007;13(3):105-17. https://doi.org/10.1097/01.nrl.0000252947.15389.a9

» https://doi.org/10.1097/01.nrl.0000252947.15389.a9

Pottie K, Thompson W, Davies S, Grenier J, Sadowski C, Welch V, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Clin Pract Guidel. 2018;64:339-351. PMID: 29760253

Ramalho-de Oliveira D, Shoemaker SJ, Ekstrand M, Alves MR. Preventing and resolving drug therapy problems by understanding patients’ medication experiences. J Am Pharm Assoc. 2012;52(1):71-80. https://doi.org/10.1331/JAPhA.2012.10239

» https://doi.org/10.1331/JAPhA.2012.10239

Reeve E, Trenaman SC, Rockwood K, Hilmer SN. Pharmacokinetic and pharmacodynamic alterations in older people with dementia. Expert Opin Drug Metab Toxicol. 2017;13(6):651-668.

Sabater D, Fernandez-Llimos F, Parras M, Faus MJ. Types of pharmacist intervention in pharmacotherapy follow-up/Tipos de intervenciones farmacéuticas en seguimiento farmacoterapéutico. Seguim Farmacoter. 2005;3(2):90-97.

Santschi V, Chiolero A, Colosimo AL, Platt RW, Taffé P, Burnier M, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3(2):e000718. https://doi.org/10.1161/JAHA.113.000718

» https://doi.org/10.1161/JAHA.113.000718

Sha T, Cheng W, Yan Y. Prospective associations between pulse pressure and cognitive performance in Chinese middle-aged and older population across a 5-year study period. Alzheimer’s Res Ther. 2018;10(1):29. https://doi.org/10.1186/s13195-018-0355-1

» https://doi.org/10.1186/s13195-018-0355-1

Silva DF, Meireles BL, Mendonça SAM, Oliveira DR. A extensão universitária como caminho para a construção do serviço de gerenciamento da terapia medicamentosa na atenção primária à saúde. Rev Bras Farm Hosp Serv Saúde São Paulo. 2016;7(2):15-21.

Smith D, Lovell J, Weller C, Kennedy B, Winbolt M, Young C, et al. A systematic review of medication nonadherence in persons with dementia or cognitive impairment. PLoS ONE. 2017;12(2):e0170651. https://doi.org/10.1371/journal.pone.0170651

» https://doi.org/10.1371/journal.pone.0170651

Strand LM, Cipolle RJ, Morley PC. Documenting the clinical pharmacist’s activities: back to basics. Drug Intell Clin Pharm. 1988;22(1):63-67. https://doi.org/10.1177/106002808802200116

» https://doi.org/10.1177/106002808802200116

World Health Organization, Dementia: a public health priority. 2012.

World Health Organization, n.d. World Alliance for Patient Health: forward programme 2008-2009. 2009, Education, 1st ed. Genebra.

Wucherer D, Thyrian JR, Eichler T, Hertel J, Kilimann I, Richter S, et al. Drug-related problems in community-dwelling primary care patients screened positive for dementia. Int Psychogeriatrics. 2017;29(11):1857-1868. https://doi.org/10.1017/S1041610217001442

» https://doi.org/10.1017/S1041610217001442

Impact of pharmacist intervention in patients with Alzheimer's disease

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

Issue

Section

License

How to Cite

Funding data